Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene to Host Research and Development Day on November 15th and 17th, 2022

* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at ...

2022-10-27 11:07 2941

Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

- XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan - Anten...

2022-10-21 20:37 4671

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 mono...

2022-10-08 10:43 1930

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

SHANGHAI and BUCKS COUNTY, Pa., Sept. 20, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Ante...

2022-09-19 09:34 1546

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office spac...

2022-09-14 08:30 3270

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Antengene to Present at Upcoming Industry Conferences

SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-09-09 14:43 1045

Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibito...

2022-09-01 08:30 2370

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update

- Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mai...

2022-08-31 08:29 2477

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavail...

2022-08-16 08:30 2707

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed ...

2022-08-03 08:30 1855

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform

- This research collaboration marks Antengene's entry into the field of cellular medicines. SHANGH...

2022-07-19 18:00 1851

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

- Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint in...

2022-06-27 08:30 2336

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-06-08 08:30 1877

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, sma...

2022-06-07 11:34 2310

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and ...

2022-06-01 08:30 2250

Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-23 10:10 2661

Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

SHANGHAI and HONG KONG, May 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-18 15:01 2483

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

-Distribution channels in place to streamline/facilitate patient access. -XPOVIO® will be available...

2022-05-16 11:20 2595

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-13 18:00 2549

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-13 08:30 2319